(Q40397862)

20 September 2017

title

Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone (English)

1 reference

20 September 2017

4

1 reference

20 September 2017

Chin-Feng Chan

3

0 references

author name string

Chih-Jung Yao

1

1 reference

20 September 2017

Gi-Ming Lai

2

1 reference

20 September 2017

Ya-Yu Yang

5

1 reference

20 September 2017

Shuang-En Chuang

6

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

International Journal of Cancer

20 September 2017

published in

1 reference

20 September 2017

volume

118

1 reference

20 September 2017

issue

3

1 reference

20 September 2017

page(s)

773-779

1 reference

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

20 September 2017

cites work

1 reference

A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer

21 January 2018

1 reference

Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study

21 January 2018

1 reference

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines

21 January 2018

1 reference

Small-molecule cyclin-dependent kinase modulators

21 January 2018

1 reference

p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers

21 January 2018

1 reference

The Rb/E2F pathway and cancer

21 January 2018

1 reference

Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death

21 January 2018

1 reference

Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism

21 January 2018

1 reference

Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs

21 January 2018

1 reference

Troglitazone induces a cellular acidosis by inhibiting acid extrusion in cultured rat mesangial cells

21 January 2018

1 reference

Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.21361

1 reference

20 September 2017

1 reference